<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00356759</url>
  </required_header>
  <id_info>
    <org_study_id>PSI-06-21</org_study_id>
    <nct_id>NCT00356759</nct_id>
  </id_info>
  <brief_title>Prolongation of the Interval Between Monitoring of Warfarin in Stable Patients</brief_title>
  <official_title>A Randomized Double-blind Study of 4-weekly Versus 12-weekly Monitoring of Stable Patients on Long-term Anticoagulation With Warfarin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hamilton Health Sciences Corporation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Physicians' Services Incorporated Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>McMaster University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with mechanical heart valve prosthesis or with irregular beat (atrial fibrillation)
      have a high risk of blood clot formation. Such clots can result in a stroke. The patients are
      treated with warfarin - a &quot;blood thinner&quot; - to prevent these complications. The treatment has
      to be monitored with a blood test called Prothrombin time (PT) every 1-4 weeks. The dose of
      warfarin has to be changed whenever the PT result is outside of the treatment range. If the
      result is too low there is an increased risk of blood clots. If, instead, the result is too
      high there is a risk of bleeding. One third of the patients have very stable PT results and
      hardly ever have to change the dose.

      The investigators hypothesis is that these patients can go less often, e.g. every 12 weeks,
      for the blood tests.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVE: The PRolongation of the INTerval between prothrombin time tests in stable patients
      (PRINT) is a single center, randomized, double-blind study to demonstrate that testing the
      prothrombin time every 12 weeks provides the same level of anticoagulant control as
      conventional testing every 4 weeks in this subset of stable patients. This study will enroll
      patients who have been treated with vitamin K antagonists (VKA) for at least 6 months and
      have not had any change to the maintenance dose for the most recent 6 months.

      HYPOTHESIS: Our hypothesis is that by extending the interval between tests to 12 weeks in
      these stable patients, the same level of anticoagulant control, can be maintained. With the
      large and constantly increasing number of patients on warfarin, a reduced frequency of
      testing would yield considerable savings for the health care system and a decreased burden
      for the patient. A review of our anticoagulant clinic revealed that one third of the patients
      would be eligible for such a prolongation of the test interval.

      STUDY DESIGN: The proposal is a randomized, double-blind, controlled single centre trial
      performed at Hamilton Health Sciences - General Hospital. Main inclusion criteria are:
      long-term anticoagulant therapy, managed by our clinic for at least 6 months and with
      unchanged maintenance dose for at least 6 months. Eligible and consenting patients identified
      at annual review visits or from the register of patients monitored by the clinic, will be
      randomized to dosing of warfarin every 4 weeks (control) or every 12 weeks (experimental).
      All patients will, however, have blood drawn every 4 weeks. Randomization will be performed
      using a computer-generated randomization sequence. Stratification is done for the two
      laboratories performing the analysis and for the two therapeutic ranges that patients are to
      be maintained within, depending on the indication for anticoagulation. Patients with
      mechanical mitral valve prosthesis are maintained between 2.5 and 3.5, others between 2.0 and
      3.0.The randomization sequence will guide the Coordinating and Methods Center to the correct
      reporting procedure for each patient, and to provide sham INR-values for two out of each set
      of three 4-weekly tests in the patients allocated to 12-weekly monitoring. Extreme INR
      results (&lt;1.5 or &gt;4.4) will always be reported as true results. The investigator and the
      patient are blind to the procedure and are only aware of the sequence order number.The
      patients are carefully instructed about risk factors that can change the effect of VKA. They
      are contacted by telephone after each test for information on the result, the dosing and for
      questioning of adverse events. After 12 months in the study there is a final visit scheduled
      at the anticoagulation clinic for review of the patient.

      ANALYSIS: After the last patient has concluded the study, all clinical data will be
      transferred to the study statistician for analysis. The primary outcome measure is &quot;the time
      in therapeutic range&quot; (TTR). The secondary outcome measures are &quot;proportion of patients with
      extreme INR results&quot;, &quot;proportion of INR results that are extreme&quot; and &quot;number of changes of
      the maintenance dose&quot;. These are well-recognized tools for evaluation of the level of
      anticoagulant control. Major bleeding and objectively verified thromboembolic events will
      also be registered, but the expected number is very small and not sufficient for any
      statistical analyses.

      SAMPLE SIZE: Sample size calculations are based on 77% TTR for a population with very stable
      VKA-dose and a maximum tolerable deviation of 7.5 percentage points; one-sided alpha of 2.5%
      and power of 90%. The sample will accordingly be 107 patients per group. After interim
      analysis the DSMB recommended to expand the sample size to 125 patients per group (July 16,
      2008).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2006</start_date>
  <completion_date type="Actual">February 2010</completion_date>
  <primary_completion_date type="Actual">January 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary Outcome Measure: Time in Therapeutic Range</measure>
    <time_frame>12 months</time_frame>
    <description>Percent time in therapeutic range calculated by linear interpolation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary Efficacy Outcomes: Thromboembolic Events</measure>
    <time_frame>12 months</time_frame>
    <description>Number of patients with any objectively verified, independently adjudicated thromboembolic event during the 12-month study period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Safety Outcome: Major Bleeding</measure>
    <time_frame>12 months</time_frame>
    <description>Number of patients with any objectively verified, independently adjudicated major bleeding event during the 12-month study period. Major bleeding was defined according to the International Society on Thrombosis and Haemostasis (ISTH) criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Safety Outcome: Number of Patients With Extreme INR Results</measure>
    <time_frame>12 months</time_frame>
    <description>Secondary safety outcome is number of patients with at least one INR below 1.5 or above 4.4</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Extreme INR Results</measure>
    <time_frame>12 months</time_frame>
    <description>Number of INRs outside the range 1.5-4.4</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients With Dose Changes</measure>
    <time_frame>12 months</time_frame>
    <description>Number of patients with at least one change of maintenance dose during the 12-month study period</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">250</enrollment>
  <condition>Atrial Fibrillation</condition>
  <condition>Heart Valve Diseases</condition>
  <condition>Venous Thrombosis</condition>
  <arm_group>
    <arm_group_label>12-weekly INR</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Dosing warfarin every 12 weeks, sham INRs 2 out of 3 times</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard management</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Dosing warfarin every 4 weeks, all INRs true values</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dosing warfarin every 12 weeks, sham INRs 2 out of 3 times</intervention_name>
    <description>Warfarin is dosed according to INR to maintain INR 2.0-3.0 or for mechanical mitral valves or mechanical aortic valves with atrial fibrillation INR 2.5-3.5</description>
    <arm_group_label>12-weekly INR</arm_group_label>
    <other_name>warfarin, Coumadin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients on long-term warfarin (for prophylaxis of arterial embolism in patients with
             atrial fibrillation or mechanical heart valve replacement, or secondary prophylaxis
             after VTE) with a target INR of 2.0-3.0 or 2.5-3.5,

          -  Anticoagulant therapy managed by the clinic (HHS - General Hospital) for at least 6
             months prior to enrolment, and

          -  Maintenance dose of warfarin unchanged for the previous 6 months or longer.

        Exclusion Criteria:

          -  Age &lt;18 years,

          -  Life expectancy of less than 1 year,

          -  Attending physician believes the patient is not suitable for the study (e.g.
             psychiatric disorder, history of non-compliance),

          -  Geographic inaccessibility or

          -  Failure to obtain written consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sam Schulman, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>McMaster University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>HHS - General Hospital, Thrombosis Service</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8L 2X2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>July 24, 2006</study_first_submitted>
  <study_first_submitted_qc>July 25, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 26, 2006</study_first_posted>
  <results_first_submitted>March 18, 2014</results_first_submitted>
  <results_first_submitted_qc>August 21, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">August 22, 2018</results_first_posted>
  <last_update_submitted>August 21, 2018</last_update_submitted>
  <last_update_submitted_qc>August 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 22, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>McMaster University</investigator_affiliation>
    <investigator_full_name>Sam Schulman</investigator_full_name>
    <investigator_title>Prof.</investigator_title>
  </responsible_party>
  <keyword>warfarin</keyword>
  <keyword>prothrombin time</keyword>
  <keyword>monitoring</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Venous Thrombosis</mesh_term>
    <mesh_term>Heart Valve Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Warfarin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Dose Assessment 4-weekly</title>
          <description>INRs and dose assessments every 4 weeks true values, no sham INRs</description>
        </group>
        <group group_id="P2">
          <title>Dose Assessment 12-weekly</title>
          <description>INRs and dose assessment 4-weekly, but 2 of 3 INRs are sham results, so dose assessment on true result is only 12-weekly</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="126"/>
                <participants group_id="P2" count="124"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="112"/>
                <participants group_id="P2" count="114"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Intercurrent disease or persistent extre</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All patients randomized</population>
      <group_list>
        <group group_id="B1">
          <title>Dose Assessment 4-weekly</title>
          <description>INRs and dose assessments every 4 weeks true values, no sham INRs</description>
        </group>
        <group group_id="B2">
          <title>Dose Assessment 12-weekly</title>
          <description>INRs and dose assessment 4-weekly, but 2 of 3 INRs are sham results, so dose assessment on true result is only 12-weekly</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="126"/>
            <count group_id="B2" value="124"/>
            <count group_id="B3" value="250"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <title>Age</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72" lower_limit="29" upper_limit="93"/>
                    <measurement group_id="B2" value="70" lower_limit="23" upper_limit="92"/>
                    <measurement group_id="B3" value="71" lower_limit="23" upper_limit="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="76"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="87"/>
                    <measurement group_id="B2" value="87"/>
                    <measurement group_id="B3" value="174"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Therapeutic INR range</title>
          <description>International normalized ratio (INR) is a standardized expression of the prothrombin time. Normal is 0.9-1.2. Therapeutic range is 2.0-3-0 for most patients, 2.5-3.5 for those with mechanical mitral valve or with mechanical aortic valve plus atrial fibrillation</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>INR range 2.0-3.0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="111"/>
                    <measurement group_id="B2" value="109"/>
                    <measurement group_id="B3" value="220"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>INR range 2.5-3.5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Primary Outcome Measure: Time in Therapeutic Range</title>
        <description>Percent time in therapeutic range calculated by linear interpolation.</description>
        <time_frame>12 months</time_frame>
        <population>Intention to treat population</population>
        <group_list>
          <group group_id="O1">
            <title>Dose Assessment 4-weekly</title>
            <description>INRs and dose assessments every 4 weeks true values, no sham INRs</description>
          </group>
          <group group_id="O2">
            <title>Dose Assessment 12-weekly</title>
            <description>INRs and dose assessment 4-weekly, but 2 of 3 INRs are sham results, so dose assessment on true result is only 12-weekly</description>
          </group>
        </group_list>
        <measure>
          <title>Primary Outcome Measure: Time in Therapeutic Range</title>
          <description>Percent time in therapeutic range calculated by linear interpolation.</description>
          <population>Intention to treat population</population>
          <units>percentage of time</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="126"/>
                <count group_id="O2" value="124"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.1" spread="18.8"/>
                    <measurement group_id="O2" value="71.6" spread="20.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Secondary Efficacy Outcomes: Thromboembolic Events</title>
        <description>Number of patients with any objectively verified, independently adjudicated thromboembolic event during the 12-month study period</description>
        <time_frame>12 months</time_frame>
        <population>Intention to treat</population>
        <group_list>
          <group group_id="O1">
            <title>Dose Assessment 4-weekly</title>
            <description>INRs and dose assessments every 4 weeks true values, no sham INRs</description>
          </group>
          <group group_id="O2">
            <title>Dose Assessment 12-weekly</title>
            <description>INRs and dose assessment 4-weekly, but 2 of 3 INRs are sham results, so dose assessment on true result is only 12-weekly</description>
          </group>
        </group_list>
        <measure>
          <title>Secondary Efficacy Outcomes: Thromboembolic Events</title>
          <description>Number of patients with any objectively verified, independently adjudicated thromboembolic event during the 12-month study period</description>
          <population>Intention to treat</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="126"/>
                <count group_id="O2" value="124"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Secondary Safety Outcome: Major Bleeding</title>
        <description>Number of patients with any objectively verified, independently adjudicated major bleeding event during the 12-month study period. Major bleeding was defined according to the International Society on Thrombosis and Haemostasis (ISTH) criteria</description>
        <time_frame>12 months</time_frame>
        <population>Intention to treat</population>
        <group_list>
          <group group_id="O1">
            <title>Dose Assessment 4-weekly</title>
            <description>INRs and dose assessments every 4 weeks true values, no sham INRs</description>
          </group>
          <group group_id="O2">
            <title>Dose Assessment 12-weekly</title>
            <description>INRs and dose assessment 4-weekly, but 2 of 3 INRs are sham results, so dose assessment on true result is only 12-weekly</description>
          </group>
        </group_list>
        <measure>
          <title>Secondary Safety Outcome: Major Bleeding</title>
          <description>Number of patients with any objectively verified, independently adjudicated major bleeding event during the 12-month study period. Major bleeding was defined according to the International Society on Thrombosis and Haemostasis (ISTH) criteria</description>
          <population>Intention to treat</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="126"/>
                <count group_id="O2" value="124"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Secondary Safety Outcome: Number of Patients With Extreme INR Results</title>
        <description>Secondary safety outcome is number of patients with at least one INR below 1.5 or above 4.4</description>
        <time_frame>12 months</time_frame>
        <population>Intention to treat</population>
        <group_list>
          <group group_id="O1">
            <title>Dose Assessment 4-weekly</title>
            <description>INRs and dose assessments every 4 weeks true values, no sham INRs</description>
          </group>
          <group group_id="O2">
            <title>Dose Assessment 12-weekly</title>
            <description>INRs and dose assessment 4-weekly, but 2 of 3 INRs are sham results, so dose assessment on true result is only 12-weekly</description>
          </group>
        </group_list>
        <measure>
          <title>Secondary Safety Outcome: Number of Patients With Extreme INR Results</title>
          <description>Secondary safety outcome is number of patients with at least one INR below 1.5 or above 4.4</description>
          <population>Intention to treat</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="126"/>
                <count group_id="O2" value="124"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Extreme INR Results</title>
        <description>Number of INRs outside the range 1.5-4.4</description>
        <time_frame>12 months</time_frame>
        <population>Intention to treat</population>
        <group_list>
          <group group_id="O1">
            <title>Dose Assessment 4-weekly</title>
            <description>INRs and dose assessments every 4 weeks true values, no sham INRs</description>
          </group>
          <group group_id="O2">
            <title>Dose Assessment 12-weekly</title>
            <description>INRs and dose assessment 4-weekly, but 2 of 3 INRs are sham results, so dose assessment on true result is only 12-weekly</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Extreme INR Results</title>
          <description>Number of INRs outside the range 1.5-4.4</description>
          <population>Intention to treat</population>
          <units>Number of tests</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="126"/>
                <count group_id="O2" value="124"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patients With Dose Changes</title>
        <description>Number of patients with at least one change of maintenance dose during the 12-month study period</description>
        <time_frame>12 months</time_frame>
        <population>Intention to treat</population>
        <group_list>
          <group group_id="O1">
            <title>Dose Assessment 4-weekly</title>
            <description>INRs and dose assessments every 4 weeks true values, no sham INRs</description>
          </group>
          <group group_id="O2">
            <title>Dose Assessment 12-weekly</title>
            <description>INRs and dose assessment 4-weekly, but 2 of 3 INRs are sham results, so dose assessment on true result is only 12-weekly</description>
          </group>
        </group_list>
        <measure>
          <title>Patients With Dose Changes</title>
          <description>Number of patients with at least one change of maintenance dose during the 12-month study period</description>
          <population>Intention to treat</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="126"/>
                <count group_id="O2" value="124"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70"/>
                    <measurement group_id="O2" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 months</time_frame>
      <desc>Fatal events are reported as serious adverse events. Non-fatal major bleeding or thromboembolism are reported as serious adverse events. Minor bleeding events are reported as non-serious (other) adverse events.</desc>
      <group_list>
        <group group_id="E1">
          <title>12-weekly INR</title>
          <description>Patients had INR every 4 weeks but only every thisrd INR was true; the other two were sham INRs dampened to be within or close to therapeutic range. Thus, true dose assessment was in practice performed every 12 weeks</description>
        </group>
        <group group_id="E2">
          <title>4-weekly INR</title>
          <description>Patients had INR every 4 weeks and all results were true. Thus, true dose assessments were performed every 4 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="124"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="124"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac death</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="124"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal bleeding</sub_title>
                <description>Melena</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="124"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Septic shock</sub_title>
                <description>Pancreatitis with fatal septic shock</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal infarct</sub_title>
                <description>Arterial embolism</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <description>Fatal respiratory failure</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="124"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="124"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Subconjunctival bleeding</sub_title>
                <description>Subconjunctival eye bleeding that did not meet criteria for major bleeding</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Rectal bleeding</sub_title>
                <description>Bleeding from rectum bleeding that did not meet criteria for major bleeding</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="124"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Hematuria</sub_title>
                <description>Urinary tract bleeding that did not meet criteria for major bleeding</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="124"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Epistaxis</sub_title>
                <description>Bleeding from the nose that did not fulfill criteria for major bleeding</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="124"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Not a truly INR monitoring and dosing every 12 weeks, because patients were tested and contacted every 4 weeks for sham results and to remind of important factors for INR instability. Extreme INR results in the 12-week group were reported unblinded.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Sam Schulman</name_or_title>
      <organization>McMaster University</organization>
      <phone>19055270271 ext 44810</phone>
      <email>schulms@mcmaster.ca</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

